Phase 3 CheckMate 067 trial of nivolumab in previously untreated advanced melanoma - European Medical Journal

Phase 3 CheckMate 067 trial of nivolumab in previously untreated advanced melanoma

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, Consultant Medical Oncologist at The Royal Marsden, London, UK, discusses the phase 3 CheckMate 067 trial. The results of this trial demonstrate a superior progression-free survival of nivolumab (a PD-1 checkpoint inhibitor) and ipilimumab (a CTLA-4 checkpoint inhibitor) regimen or nivolumab monotherapy versus ipilimumab monotherapy in previously untreated advanced melanoma.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given